Andrew Perry
Non-small cell lung cancer (NSCLC) is responsible for roughly 27% of all cancer-related fatalities globally, making it a serious public health issue. Healing needs full, indefinitely-lasting tumor removal (usually by surgery or radiation [RT]), although substantial shrinking (typically by systemic therapies) might result in long-term disease management. More realistically, in the absence of treatments, hosttumor interactions, which are major determinants in the natural history of diseases, will have a significant impact on disease progression, with treatments primarily aimed at causing the host-tumor balance to tip toward improvement or, if possible, healing.
分享此文章